Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release.
Synthetic 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (PAF) and 1-O-alkyl-sn-glyceryl-3-phosphorylcholine (lyso-PAF) have previously been shown to induce chemotaxis and chemokinesis of human neutrophils. We present here data showing that these agents are inactive by themselves, but that they enhance neutrophil secretion once it has been initiated by a calcium ionophore or by zymosan. Two substances, the lipid eosinophil chemotactic factor (ECF) and the lysosomal enzyme beta-glucuronidase, are used as markers for neutrophil release. PAF augments secretion of both substances in a dose-dependent fashion, with lyso-PAF being less potent. The kinetics of enhancement are very rapid (less than 2 min) and are not reversible by washing of the cells. A pyrazoline derivative that inhibits arachidonate cyclo-oxygenation and lipoxygenation, reduces the enhancing effect of PAF and lyso-PAF. PAF, and less so lyso-PAF, are thus potentially important modulators of neutrophil secretion during inflammatory processes.
D000001:Calcimycin / Q000494:pharmacology; D002630:Chemotactic Factors / Q000378:metabolism*; D002631:Chemotactic Factors, Eosinophil / Q000378:metabolism*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003165:Complement System Proteins / Q000378:metabolism; D004357:Drug Synergism; D004804:Eosinophils / Q000378:metabolism; D005966:Glucuronidase / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000209:etiology; D009504:Neutrophils / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000502:physiology*; D015054:Zymosan / Q000494:pharmacology
D002630:Chemotactic Factors; D002631:Chemotactic Factors, Eosinophil; C029271:O-deacetyl platelet activating factor; D010972:Platelet Activating Factor; D000001:Calcimycin; D003165:Complement System Proteins; D015054:Zymosan; D005966:Glucuronidase